A new combination adjuvant approach
TRAC478 is a new combination adjuvant approach in which INI-2002, a TLR4 adjuvant, and INI-4001, a TLR7/8 adjuvant are used together to generate synergistic immune responses. Pre-clinically, TRAC478 results in strong Th1-biased antibody and T cell responses and is efficacious in influenza challenge models. TRAC478 can be used with a number of different vaccine formulations, each of which influences the adjuvant-mediated immune response to better tailor the response to protect against a particular pathogen.
Both INI-2002 and INI-4001 have been manufactured under cGMP conditions and cGMP production of of a TRAC478 emulsion drug product is underway. The first human use of TRAC478 is expected in a 2025 NIH-funded influenza vaccine clinical trial as part of the CIVICs (Collaborative Influenza Vaccine Innovation Centers) program.
